Global Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook 2022

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook 2022

Table of Contents
1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2016-2027
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2027
1.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Manufacturers
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
3.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.6.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.6.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
3.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Type
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2016-2021)
5 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Analysis by Application
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Astellas Pharma
6.3.1 Astellas Pharma Corporation Information
6.3.2 Astellas Pharma Description and Business Overview
6.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.3.5 Astellas Pharma Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.6.5 Abbott Recent Developments/Updates
6.7 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description and Business Overview
6.6.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.7.5 Allergan Recent Developments/Updates
6.8 TEVA
6.8.1 TEVA Corporation Information
6.8.2 TEVA Description and Business Overview
6.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.8.5 TEVA Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Corporation Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Description and Business Overview
6.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
6.11.5 Merck Recent Developments/Updates
7 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
7.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
8.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
9 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
9.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
9.2 Benign Prostatic Hyperplasia (BPH) Drugs Growth Drivers
9.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
9.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
10 Global Market Forecast
10.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2022-2027)
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2022-2027)
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Comparison by Application (2021-2027)
Table 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Covered in This Study
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) of Key Manufacturers (2016-2021)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 19. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 23. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2016-2021) & (M Units)
Table 27. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 31. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2016-2021) & (M Units)
Table 35. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2016-2021)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2016-2021)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Type (2016-2021)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Application (2016-2021)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2016-2021)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (US$/Unit) by Application (2016-2021)
Table 48. Eli Lilly Corporation Information
Table 49. Eli Lilly Description and Business Overview
Table 50. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 52. Eli Lilly Recent Developments/Updates
Table 53. GlaxoSmithKline Corporation Information
Table 54. GlaxoSmithKline Description and Business Overview
Table 55. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 57. GlaxoSmithKline Recent Developments/Updates
Table 58. Astellas Pharma Corporation Information
Table 59. Astellas Pharma Description and Business Overview
Table 60. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 62. Astellas Pharma Recent Developments/Updates
Table 63. Sanofi Corporation Information
Table 64. Sanofi Description and Business Overview
Table 65. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 67. Sanofi Recent Developments/Updates
Table 68. Pfizer Corporation Information
Table 69. Pfizer Description and Business Overview
Table 70. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 72. Pfizer Recent Developments/Updates
Table 73. Abbott Corporation Information
Table 74. Abbott Description and Business Overview
Table 75. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 77. Abbott Recent Developments/Updates
Table 78. Allergan Corporation Information
Table 79. Allergan Description and Business Overview
Table 80. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 82. Allergan Recent Developments/Updates
Table 83. TEVA Corporation Information
Table 84. TEVA Description and Business Overview
Table 85. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 87. TEVA Recent Developments/Updates
Table 88. Mylan Corporation Information
Table 89. Mylan Description and Business Overview
Table 90. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 92. Mylan Recent Developments/Updates
Table 93. Novartis Corporation Information
Table 94. Novartis Description and Business Overview
Table 95. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 97. Novartis Recent Developments/Updates
Table 98. Merck Corporation Information
Table 99. Merck Description and Business Overview
Table 100. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 102. Merck Recent Developments/Updates
Table 103. Production Base and Market Concentration Rate of Raw Material
Table 104. Key Suppliers of Raw Materials
Table 105. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 106. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 107. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 108. Benign Prostatic Hyperplasia (BPH) Drugs Growth Drivers
Table 109. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 110. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 111. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2022-2027) & (M Units)
Table 112. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2022-2027)
Table 113. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 114. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 115. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2022-2027) & (M Units)
Table 116. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2022-2027)
Table 117. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 118. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 119. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2022-2027) & (M Units)
Table 120. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2022-2027)
Table 121. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 122. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2020 & 2027
Figure 3. Alpha-Blocker Product Picture
Figure 4. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 5. Others Product Picture
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2020 & 2027
Figure 7. Hospitals
Figure 8. Drugstores
Figure 9. Others
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size 2016-2027 (US$ Million)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2016-2027 (M Units)
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers in 2020
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players: Market Share by Revenue in 2020
Figure 17. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2016-2021)
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2020
Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2016-2021)
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2020
Figure 22. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Philippines Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Vietnam Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. UAE Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2016-2021)
Figure 47. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2016-2021)
Figure 48. Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2020
Figure 49. Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2016-2021)
Figure 50. Revenue Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2020
Figure 51. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 52. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 53. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Histone Deacetylase (HDAC) Inhibitors Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 87

The global Histone Deacetylase (HDAC) Inhibitors market was valued at US$ 615.2 million in 2023 and is anticipated to reach US$ 1223.2 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. North American market for Histone Deacetylase (HDAC) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Histone Deacetylase (HDAC) Inhibitor......

Global Esomeprazole Magnesium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 74

The global Esomeprazole Magnesium market was valued at US$ 5287 million in 2023 and is anticipated to reach US$ 9451.5 million by 2030, witnessing a CAGR of 8.3% during The forecast period 2024-2030. North American market for Esomeprazole Magnesium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Esomeprazole Magnesium is estimated to increase from $ million in 2......

Global Combination Therapy Drug Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Combination Therapy Drug market was valued at US$ 105 million in 2023 and is anticipated to reach US$ 166.7 million by 2030, witnessing a CAGR of 4.1% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is......

Global Axitinib Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 68

The global Axitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Axitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The......

Global Lyme Disease Vaccine Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 70

The lyme disease vaccine can reduce lyme disease incidence, reduce symptoms and reduce mortality. Lyme disease is a tick-borne infection of spirochete, a natural disease caused by borrelia burgdorferi. The global Lyme Disease Vaccine market was valued at US$ 257 million in 2023 and is anticipated to reach US$ 763 million by 2030, witnessing a CAGR of 8.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at......

Global Transdermal Absorption Patch Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Transdermal Absorption Patch market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Transdermal Absorption Patch is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Transdermal Absorption Patch is estimated to increase from $ million i......

Global Ketoprofen Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

Ketoprofen patch, indications for The treatment of symptoms caused by The following diseases: rheumatoid arthritis and rheumatoid arthritis The global Ketoprofen Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Ketoprofen Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast per......

Global Methyl Salicylate Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 82

The global Methyl Salicylate Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Methyl Salicylate Patches is estimated to increase from $ million in 2023 to......

Global Diclofenac Patches Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Diclofenac Patches market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Diclofenac Patches is estimated to increase from $ million in 2023 to reach $ million by 2......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs